Large Language Models (LLMs) employ three popular training approaches: Masked Language Models (MLM), Causal Language Models (CLM), and Sequence-to-Sequence Models (seq2seq). However, each approach has its strengths and limitations, and faces challenges in addressing specific tasks that require controllable and bidirectional generation, such as drug optimization. To address this challenge, inspired by the biological processes of growth and evolution, which involve the expansion, shrinking, and mutation of sequences, we introduce ControllableGPT. This initiative represents the first effort to combine the advantages of MLM, CLM, and seq2seq into a single unified, controllable GPT framework. It enables the precise management of specific locations and ranges within a sequence, allowing for expansion, reduction, or mutation over chosen or random lengths, while maintaining the integrity of any specified positions or subsequences. In this work, we designed ControllableGPT for drug optimization from the ground up, which included proposing the Causally Masked Seq2seq (CMS) objective, developing the training corpus, introducing a novel pre-training approach, and devising a unique generation process. We demonstrate the effectiveness and controllability of ControllableGPT by conducting experiments on drug optimization tasks for both viral and cancer benchmarks, surpassing competing baselines.

Deep neural networks have enabled researchers to create powerful generalized frameworks, such as transformers, that can be used to solve well-studied problems in various application domains, such as text and image. However, such generalized frameworks are not available for solving graph problems. Graph structures are ubiquitous in many applications around us and many graph problems have been widely studied over years. In recent times, there has been a surge in deep neural network based approaches to solve graph problems, with growing availability of graph structured datasets across diverse domains. Nevertheless, existing methods are mostly tailored to solve a specific task and lack the capability to create a generalized model leading to solutions for different downstream tasks. In this work, we propose a novel, resource-efficient framework named \emph{U}nified \emph{G}raph \emph{N}etwork (UGN) by leveraging the feature extraction capability of graph convolutional neural networks (GCN) and 2-dimensional convolutional neural networks (Conv2D). UGN unifies various graph learning tasks, such as link prediction, node classification, community detection, graph-to-graph translation, knowledge graph completion, and more, within a cohesive framework, while exercising minimal task-specific extensions (e.g., formation of supernodes for coarsening massive networks to increase scalability, use of \textit{mean target connectivity matrix} (MTCM) representation for achieving scalability in graph translation task, etc.) to enhance the generalization capability of graph learning and analysis. We test the novel UGN framework for six uncorrelated graph problems, using twelve different datasets. Experimental results show that UGN outperforms the state-of-the-art baselines by a significant margin on ten datasets, while producing comparable results on the remaining dataset.

Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research delves into the realm of drug optimization and introduce a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model, enhancing the original drug across target objectives, while retains the beneficial chemical properties of the original drug. This work is comprised of two primary components: (1) DrugImprover: A framework tailored for improving robustness and efficiency in drug optimization. It includes a LLM designed for drug optimization and a novel Structured Policy Optimization (SPO) algorithm, which is theoretically grounded. This algorithm offers a unique perspective for fine-tuning the LLM-based generative model by aligning the improvement of the generated molecule with the input molecule under desired objectives. (2) A dataset of 1 million compounds, each with OEDOCK docking scores on 5 human proteins associated with cancer cells and 24 binding sites from SARS-CoV-2 virus. We conduct a comprehensive evaluation of SPO and demonstrate its effectiveness in improving the original drug across target properties. Our code and dataset will be publicly available at: https://github.com/xuefeng-cs/DrugImproverGPT.

Drug-side effect research is vital for understanding adverse reactions arising in complex multi-drug therapies. However, the scarcity of higher-order datasets that capture the combinatorial effects of multiple drugs severely limits progress in this field. Existing resources such as TWOSIDES primarily focus on pairwise interactions. To fill this critical gap, we introduce HODDI, the first Higher-Order Drug-Drug Interaction Dataset, constructed from U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) records spanning the past decade, to advance computational pharmacovigilance. HODDI contains 109,744 records involving 2,506 unique drugs and 4,569 unique side effects, specifically curated to capture multi-drug interactions and their collective impact on adverse effects. Comprehensive statistical analyses demonstrate HODDI's extensive coverage and robust analytical metrics, making it a valuable resource for studying higher-order drug relationships. Evaluating HODDI with multiple models, we found that simple Multi-Layer Perceptron (MLP) can outperform graph models, while hypergraph models demonstrate superior performance in capturing complex multi-drug interactions, further validating HODDI's effectiveness. Our findings highlight the inherent value of higher-order information in drug-side effect prediction and position HODDI as a benchmark dataset for advancing research in pharmacovigilance, drug safety, and personalized medicine. The dataset and codes are available at https://github.com/TIML-Group/HODDI.

Drug optimization has become increasingly crucial in light of fast-mutating virus strains and drug-resistant cancer cells. Nevertheless, it remains challenging as it necessitates retaining the beneficial properties of the original drug while simultaneously enhancing desired attributes beyond its scope. In this work, we aim to tackle this challenge by introducing ScaffoldGPT, a novel Large Language Model (LLM) designed for drug optimization based on molecular scaffolds. Our work comprises three key components: (1) A three-stage drug optimization approach that integrates pretraining, finetuning, and decoding optimization. (2) A uniquely designed two-phase incremental training approach for pre-training the drug optimization LLM-based generator on molecule scaffold with enhanced performance. (3) A token-level decoding optimization strategy, TOP-N, that enabling controlled, reward-guided generation using pretrained/finetuned LLMs. Finally, by conducting a comprehensive evaluation on COVID and cancer benchmarks, we demonstrate that SCAFFOLDGPT outperforms the competing baselines in drug optimization benchmarks, while excelling in preserving the original functional scaffold and enhancing desired properties.

Drug development is a critical but notoriously resource- and time-consuming process. In this manuscript, we develop a novel generative artificial intelligence (genAI) method DiffSMol to facilitate drug development. DiffSmol generates 3D binding molecules based on the shapes of known ligands. DiffSMol encapsulates geometric details of ligand shapes within pre-trained, expressive shape embeddings and then generates new binding molecules through a diffusion model. DiffSMol further modifies the generated 3D structures iteratively via shape guidance to better resemble the ligand shapes. It also tailors the generated molecules toward optimal binding affinities under the guidance of protein pockets. Here, we show that DiffSMol outperforms the state-of-the-art methods on benchmark datasets. When generating binding molecules resembling ligand shapes, DiffSMol with shape guidance achieves a success rate 61.4%, substantially outperforming the best baseline (11.2%), meanwhile producing molecules with novel molecular graph structures. DiffSMol with pocket guidance also outperforms the best baseline in binding affinities by 13.2%, and even by 17.7% when combined with shape guidance. Case studies for two critical drug targets demonstrate very favorable physicochemical and pharmacokinetic properties of the generated molecules, thus, the potential of DiffSMol in developing promising drug candidates.

Monoclonal antibodies (mAbs) represent one of the most prevalent FDA-approved modalities for treating autoimmune diseases, infectious diseases, and cancers. However, discovery and development of therapeutic antibodies remains a time-consuming and expensive process. Recent advancements in machine learning (ML) and artificial intelligence (AI) have shown significant promise in revolutionizing antibody discovery and optimization. In particular, models that predict antibody biological activity enable in-silico evaluation of binding and functional properties; such models can prioritize antibodies with the highest likelihoods of success in costly and time-intensive laboratory testing procedures. We here explore an AI model for predicting the binding and receptor blocking activity of antibodies against influenza A hemagglutinin (HA) antigens. Our present model is developed with the MAMMAL framework for biologics discovery to predict antibody-antigen interactions using only sequence information. To evaluate the model's performance, we tested it under various data split conditions to mimic real-world scenarios. Our models achieved an AUROC $\geq$ 0.91 for predicting the activity of existing antibodies against seen HAs and an AUROC of 0.9 for unseen HAs. For novel antibody activity prediction, the AUROC was 0.73, which further declined to 0.63-0.66 under stringent constraints on similarity to existing antibodies. These results demonstrate the potential of AI foundation models to transform antibody design by reducing dependence on extensive laboratory testing and enabling more efficient prioritization of antibody candidates. Moreover, our findings emphasize the critical importance of diverse and comprehensive antibody datasets to improve the generalization of prediction models, particularly for novel antibody development.

One of the LPDI's de novo protein binders (red) bound to the protein Bcl2 (blue) in complex with FDA-approved drug Venetoclax (beige) LPDI EPFL In 2023, scientists in the joint School of Engineering and School of Life Sciences Laboratory of Protein Design and Immunoengineering (LPDI), led by Bruno Correia, published a deep-learning pipeline for designing new proteins to interact with therapeutic targets. MaSIF can rapidly scan millions of proteins to identify optimal matches between molecules based on their chemical and geometric surface properties, enabling scientists to engineer novel protein-protein interactions that play key roles in cell regulation and therapeutics. A year and a half later, the team has reported an exciting advancement of this technology. They have used MaSIF to design novel protein binders to interact with known protein complexes involving small molecules like therapeutic drugs or hormones. Because these bound small molecules induce subtle changes in the surface properties ('neosurfaces') of these protein-drug complexes, they can act as'on' or'off' switches for the fine control of cellular functions like DNA transcription or protein degradation.

Antibiotics are often grouped by their mechanisms of action, such as blocking protein synthesis, disrupting folate biosynthesis, changing cell wall construction, compromising the cell membrane integrity and affecting DNA replication [93, 25]. These antibiotics, whether created in labs or found in nature, serve as the primary defence against bacterial infections. However, bacteria employ a series of strategies in response to resist these antibiotics, including inactivating antibiotics through enzymatic degradation, altering the antibiotic target, modifying cell membrane permeability, and using efflux pumps to maintain intracellular antibiotic concentrations of antibiotics below inhibitory levels [25]. Moreover, the gene transfer of antibiotic-resistant bacteria (ARB) further aggravates this challenge [92].

Modern machine learning produces models that are impossible for users or developers to fully understand -- raising concerns about trust, oversight and human dignity. Transparency and explainability methods aim to provide some help in understanding models, but it remains challenging for developers to design explanations that are understandable to target users and effective for their purpose. Emerging guidelines and regulations set goals but may not provide effective actionable guidance to developers. In a controlled experiment with 124 participants, we investigate whether and how specific forms of policy guidance help developers design explanations for an ML-powered screening tool for diabetic retinopathy. Contrary to our expectations, we found that participants across the board struggled to produce quality explanations, comply with the provided policy requirements for explainability, and provide evidence of compliance. We posit that participant noncompliance is in part due to a failure to imagine and anticipate the needs of their audience, particularly non-technical stakeholders. Drawing on cognitive process theory and the sociological imagination to contextualize participants' failure, we recommend educational interventions.